MK 1075

Drug Profile

MK 1075

Alternative Names: MK1075

Latest Information Update: 03 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Sharp & Dohme
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis C

Most Recent Events

  • 01 Dec 2015 Merck Sharp and Dohme completes a phase I trial for Hepatitis C (genotype 1 and genotype 2) in Belgium and Moldova (NCT02461563)
  • 01 Aug 2015 Merck Sharp and Dohme completed a phase I trial in Hepatitis C in Belgium (NCT02392494)
  • 08 Jun 2015 Merck Sharp and Dohme plans a phase I trial for Hepatitis C (genotype 1 and genotype 2) in Belgium and Moldova (NCT02461563)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top